Trial · NCT00062439

S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors

NCT00062439, Phase 2, Completed, SWOG Cancer Research Network; results first posted 2013-11-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors. Trials, record NCT00062439. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00062439

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
NCT number: NCT00062439
Status: Completed
Phases: Phase 2
Enrollment: 46 participants, actual
Lead sponsor: SWOG Cancer Research Network
Conditions: Lung Cancer
Interventions: cisplatin, docetaxel, etoposide, conventional surgery, radiation therapy
First posted: 2003-06-06
Last updated: 2013-11-25
Results first posted: 2013-11-25

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Feasibility of Treating Patients With Stage IIB/IIIB Pancoast Tumors With a Regimen of Cisplatin and Etoposide Plus Concurrent Radiotherapy Followed by Surgical Resection Followed by Consolidation Therapy With Docetaxel.	After completion of 5 weeks of radiotherapy given concurrently with cisplatin+etoposide, surgery + 8 weeks of recovery time, and 6 weeks of consolidation therapy with docetaxel	Feasibility was assessed by estimating the percentage of participants who would be able to complete the entire treatment regimen.
Secondary	Adverse Events	Weekly for the first 13 weeks, then every 3 weeks for the next 6 weeks.	Only adverse events that are possibly, probably or definitely related to study drug are reported.
Secondary	Overall Survival	daily for 12 weeks then every 3 weeks for 12 weeks, then every 6 months thereafter.	The duration from the date of enrollment until the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.
Secondary	Progression-Free Survival at 3 Years	At the completion of induction therapy, then again 4 weeks after the completion of consolidation therapy, then every 3 months for 2 years, then every 6 months until up to a maximum of 5 years after enrollment.	Duration from date of enrollment to date of progression (per RECIST), symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at the date of last contact.
Secondary	Response	After completion of induction therapy.	Response was defined as achieving a confirmed or unconfirmed complete or partial response as determined by RECIST. Patients who dropped out due to any cause prior to getting their response assessment were counted as non-responders. A complete response (CR) was defined as disappearance of all disease. A partial response was defined as a \>= 30% decrease in the sum of longest diameters of target lesions. A CR or PR was defined as confirmed if two consecutive determinations were documented at least 4 weeks apart.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
SECONDARY	Adverse Events	Weekly for the first 13 weeks, then every 3 weeks for the next 6 weeks.	Eligible patients who received the study intervention.	Participants	NUMBER
PRIMARY	Feasibility of Treating Patients With Stage IIB/IIIB Pancoast Tumors With a Regimen of Cisplatin and Etoposide Plus Concurrent Radiotherapy Followed by Surgical Resection Followed by Consolidation Therapy With Docetaxel.	After completion of 5 weeks of radiotherapy given concurrently with cisplatin+etoposide, surgery + 8 weeks of recovery time, and 6 weeks of consolidation therapy with docetaxel	Eligible patients who began the treatment regimen were included in the analysis.	percentage of participants	NUMBER
SECONDARY	Overall Survival	daily for 12 weeks then every 3 weeks for 12 weeks, then every 6 months thereafter.	Eligible patients who began the treatment regimen were included in the analysis.	years	MEDIAN
SECONDARY	Progression-Free Survival at 3 Years	At the completion of induction therapy, then again 4 weeks after the completion of consolidation therapy, then every 3 months for 2 years, then every 6 months until up to a maximum of 5 years after enrollment.	Eligible patients who began the treatment regimen were included in the analysis.	percentage of patients	NUMBER
SECONDARY	Response	After completion of induction therapy.	Eligible patients who began the treatment regimen and who had measurable disease (per RECIST) at baseline were included in the analysis of response.	percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group130

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Adverse Events	Induction Cisplatin/Etoposide + XRT	Adult respiratory distress syndrome (ARDS)	0	Participants
Adverse Events	Surgery	Adult respiratory distress syndrome (ARDS)	3	Participants
Adverse Events	Consolidation Docetaxel	Adult respiratory distress syndrome (ARDS)	0	Participants
Adverse Events	Induction Cisplatin/Etoposide + XRT	Allergic reaction/hypersensitivity	1	Participants
Adverse Events	Surgery	Allergic reaction/hypersensitivity	0	Participants
Adverse Events	Consolidation Docetaxel	Allergic reaction/hypersensitivity	0	Participants
Adverse Events	Induction Cisplatin/Etoposide + XRT	Chylothorax	0	Participants
Adverse Events	Surgery	Chylothorax	2	Participants
Adverse Events	Consolidation Docetaxel	Chylothorax	0	Participants
Adverse Events	Induction Cisplatin/Etoposide + XRT	Dehydration	2	Participants

1 to 10 of 130Source ClinicalTrials.gov

See all 130 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Induction Chemotherapy + Radiotherapy	STARTED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	46
Induction Chemotherapy + Radiotherapy	COMPLETED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	38
Induction Chemotherapy + Radiotherapy	NOT COMPLETED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	8
Post Chemoradiation Assessment	STARTED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	38
Post Chemoradiation Assessment	COMPLETED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	29
Post Chemoradiation Assessment	NOT COMPLETED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	9
Surgery	STARTED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	29
Surgery	COMPLETED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	22
Surgery	NOT COMPLETED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	7
Consolidation Chemotherapy	STARTED	Induction Cisplatin/Etoposide + XRT/Surgery/Consolidation Chem	22

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events195

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Hemoglobin	Blood and lymphatic system disorders	Induction Cisplatin/Etoposide + XRT	28	44
other	Hemoglobin	Blood and lymphatic system disorders	Surgery	16	29
other	Hemoglobin	Blood and lymphatic system disorders	Consolidation Docetaxel	13	22
other	SVT and nodal arrhythmia - Atrial fibrillation	Cardiac disorders	Induction Cisplatin/Etoposide + XRT	0	44
other	SVT and nodal arrhythmia - Atrial fibrillation	Cardiac disorders	Surgery	3	29
other	SVT and nodal arrhythmia - Atrial fibrillation	Cardiac disorders	Consolidation Docetaxel	0	22
other	SVT and nodal arrhythmia - Atrial flutter	Cardiac disorders	Induction Cisplatin/Etoposide + XRT	0	44
other	SVT and nodal arrhythmia - Atrial flutter	Cardiac disorders	Surgery	2	29
other	SVT and nodal arrhythmia - Atrial flutter	Cardiac disorders	Consolidation Docetaxel	0	22
other	SVT and nodal arrhythmia - SVT arrhythmia NOS	Cardiac disorders	Induction Cisplatin/Etoposide + XRT	0	44

1 to 10 of 195Source ClinicalTrials.gov

See all 195 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Induction Cisplatin/Etoposide + XRT
Total, all-cause mortality	Surgery
Total, all-cause mortality	Consolidation Docetaxel
Total, other adverse events	Induction Cisplatin/Etoposide + XRT	43	44
Total, other adverse events	Surgery	26	29
Total, other adverse events	Consolidation Docetaxel	21	22
Total, serious adverse events	Induction Cisplatin/Etoposide + XRT	1	44
Total, serious adverse events	Surgery	3	29
Total, serious adverse events	Consolidation Docetaxel	0	22

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA032102	Southwest Oncology Group Treatment Grant	BLANKE, CHARLES D.	OREGON HEALTH & SCIENCE UNIVERSITY	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00062439

GET https://conductscience.org/api/trials/v1/NCT00062439/results?page=2

API reference For AI assistants